Nucleoside analogues in untreated Waldenström’s macroglobulinemia (reviewed in Merlini and Treon21 ).
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | ||||
| b Mean number of infusions. | ||||
| Abbreviations: RR, response rate; NA, not applicable. | ||||
| Cladribine | ||||
| Dimopoulos | 26 | 2 | 85% | 2+–39+ months |
| Delannoy | 5 | 2 | 40% | NA |
| Fridrik | 10 | 4 | 90% | NA |
| Liu | 7 | 3 | 57% | NA |
| Hellman | 9 | 4 | 44% | NA |
| Fludarabine | ||||
| Dimopoulos | 2 | 3 | 100% | NA |
| Foran | 15 | 5.2b | 79% | 40 months |
| Thalhammer-Scherrer | 7 | 6 | 85% | 44+ months |
| Dhodapkar | 118 | 4–8 | 38% | 59 months |
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | ||||
| b Mean number of infusions. | ||||
| Abbreviations: RR, response rate; NA, not applicable. | ||||
| Cladribine | ||||
| Dimopoulos | 26 | 2 | 85% | 2+–39+ months |
| Delannoy | 5 | 2 | 40% | NA |
| Fridrik | 10 | 4 | 90% | NA |
| Liu | 7 | 3 | 57% | NA |
| Hellman | 9 | 4 | 44% | NA |
| Fludarabine | ||||
| Dimopoulos | 2 | 3 | 100% | NA |
| Foran | 15 | 5.2b | 79% | 40 months |
| Thalhammer-Scherrer | 7 | 6 | 85% | 44+ months |
| Dhodapkar | 118 | 4–8 | 38% | 59 months |